Financial Performance - In 2019, the company's operating revenue was CNY 262,017,718.33, a decrease of 37.49% compared to CNY 419,189,442.94 in 2018[19] - The net profit attributable to shareholders in 2019 was CNY 34,384,702.06, a significant improvement of 105.09% from a loss of CNY 675,291,477.07 in 2018[19] - Basic earnings per share for 2019 were CNY 0.0860, a turnaround from a loss of CNY 1.6866 in 2018, marking a 105.10% increase[21] - The weighted average return on equity improved to 3.68% in 2019, an increase of 52.48 percentage points from -48.80% in 2018[21] - The company reported a net cash flow from operating activities of -CNY 6,795,414.33 in 2019, a decline of 108.44% compared to CNY 80,553,717.37 in 2018[19] - The cumulative distributable profit for the company was negative at -CNY 1,678,504,740.43, leading to no cash dividend distribution for 2019[5] - The company reported non-recurring gains of ¥27,073,595.13 for the year 2019, compared to ¥143,509,581.00 in 2018, indicating a significant decrease[25] Assets and Liabilities - The company's total assets at the end of 2019 were CNY 1,291,205,717.74, reflecting a 3.43% increase from CNY 1,248,330,745.21 in 2018[20] - The net asset attributable to shareholders increased to CNY 954,695,566.45, up 4.49% from CNY 913,643,129.67 in 2018[20] - The company recognized an impairment loss of 17.55 million yuan for the Huawai Pharmaceutical asset group, with a cumulative impairment provision of 1.548 billion yuan[34] - The company reported a goodwill impairment provision of 17.55 million, impacting profits significantly[62] - The company’s accounts payable decreased by 44.41% to 40.59 million compared to the previous period[65] Revenue Breakdown - Revenue from pharmaceutical R&D decreased by CNY 92.67 million to CNY 114.54 million, with a gross margin reduction of 2.43%[54] - Clinical trial revenue decreased by CNY 18.98 million to CNY 116.17 million, with a gross margin decrease of 0.4%[54] - Other pharmaceutical income from intermediates was CNY 1.59 million, a decrease of 36.24%[55] - Domestic sales revenue was CNY 262 million, with a gross margin of 48.49%, an increase of 1.83 percentage points year-on-year[55] Operational Changes and Strategies - The company plans to enhance its core competitiveness by increasing investment in innovative drug research and development, focusing on original innovative drugs as a market value hotspot[31] - The company aims to expand its clinical service business for innovative drugs and strengthen strategic cooperation with major pharmaceutical companies[43] - The company has established new subsidiaries, including Liwei Biopharmaceuticals and Xipuda Data Management Company, to enhance its drug research and data management capabilities[44] - The company has implemented a comprehensive budget management system to improve operational control and reduce non-operational expenses[42] - The company aims to strengthen risk prediction and control systems across various business segments, including drug research and clinical services, to ensure healthy operations[80] Corporate Governance and Compliance - The company has made significant changes to its governance structure, including the appointment of new directors and supervisors to align with its strategic goals[41] - The company confirmed that it will not engage in any drug research and development activities directly or indirectly in any region after the completion of the major asset restructuring[89] - The company will strictly adhere to the decision-making procedures for related party transactions and ensure timely disclosure of such transactions[88] - The company has committed to avoiding related party transactions post-restructuring to protect shareholder interests[90] - The company has established a commitment to comply with all relevant laws and regulations in its operations and transactions[92] Shareholder Information - The top shareholder, Xinjiang Hualing Industrial Trade Group Co., Ltd., holds 79,525,087 shares, representing 19.86% of the total shares[127] - The total number of ordinary shareholders as of the end of the reporting period is 12,915, an increase from 12,027 at the end of the previous month[125] - The total number of shares held by the top ten unrestricted shareholders is 129,000,000, indicating strong support from major investors[128] - The company has not disclosed any related party relationships among the top shareholders[128] Employee and Labor Information - The total number of employees in the parent company is 47, while the main subsidiaries employ 809, resulting in a total of 856 employees[149] - The professional composition includes 721 technical personnel, 63 administrative staff, and 14 sales personnel[149] - The total remuneration paid to directors, supervisors, and senior management during the reporting period is 438.5[146] - The company has implemented a composite compensation system consisting of basic salary, performance pay, and various subsidies, ensuring timely and full payment of social insurance and housing fund for employees[150] Internal Control and Audit - The internal control evaluation report confirms the effectiveness of the company's internal control system as of December 31, 2019[162] - The company has established a self-evaluation and internal audit mechanism to address any identified internal control deficiencies promptly[180] - The audit report confirmed that the financial statements fairly reflect the company's financial position as of December 31, 2019[187] - The company is committed to maintaining compliance with accounting standards and ensuring the accuracy of financial reporting[196]

Financial Performance - Operating revenue fell by 51.31% to CNY 34,305,703.24 year-on-year[5] - Net profit attributable to shareholders decreased by 89.31% to CNY 2,830,693.04 compared to the same period last year[5] - Basic earnings per share dropped by 89.26% to CNY 0.0071[5] - The company reported a significant decline in net profit due to reduced operating revenue and increased costs[5] - Total operating revenue for Q1 2020 was ¥34,305,703.24, a decrease of 51.3% compared to ¥70,454,860.94 in Q1 2019[30] - Net profit for Q1 2020 was ¥2,830,693.04, a decline of 89.2% from ¥26,308,541.27 in Q1 2019[31] - Operating profit for Q1 2020 was ¥2,537,849.33, down 91.5% from ¥29,788,442.90 in Q1 2019[31] - Other income for Q1 2020 was ¥696,413.61, a decrease from ¥1,558,786.00 in Q1 2019[31] Assets and Liabilities - Total assets decreased by 3.66% to CNY 1,243,956,919.75 compared to the end of the previous year[5] - The company's cash and cash equivalents decreased by 51.39% to CNY 24.85 million from CNY 51.12 million at the beginning of the period[15] - Accounts receivable decreased significantly by 89.58% to CNY 25.40 million from CNY 235.08 million[21] - Inventory increased by 20.00% to CNY 284.87 million from CNY 236.93 million[14] - Total liabilities decreased by 32.08% to CNY 8.50 million from CNY 12.54 million[14] - Total assets decreased from CNY 1,291,205,717.74 to CNY 1,243,956,919.75, a decline of approximately 3.65%[24] - Current liabilities increased from CNY 270,933,683.21 to CNY 318,308,190.68, an increase of about 17.54%[23] - Total liabilities rose from CNY 336,510,151.29 to CNY 384,408,940.08, reflecting an increase of around 14.23%[23] - The company's equity attributable to shareholders decreased from CNY 954,695,566.45 to CNY 859,547,979.67, a decline of about 9.95%[24] Cash Flow - Cash flow from operating activities improved by 56.28%, reaching a net cash flow of -21,235,073.15[5] - Cash inflow from operating activities in Q1 2020 was CNY 52,743,048.39, down 19.4% from CNY 65,461,677.50 in Q1 2019[37] - Cash outflow from operating activities in Q1 2020 totaled CNY 73,978,121.54, a decrease of 35.2% from CNY 114,030,995.75 in Q1 2019[37] - Net cash flow from operating activities was negative CNY 21,235,073.15, an improvement from negative CNY 48,569,318.25 in Q1 2019[37] - Cash flow from investing activities was negative CNY 4,816,814.87 in Q1 2020, compared to a positive cash flow of CNY 25,860,185.69 in Q1 2019[38] - The company reported a net cash outflow of CNY 26,271,804.68 in Q1 2020, compared to a net outflow of CNY 25,621,363.78 in Q1 2019[38] Shareholder Information - The total number of shareholders reached 12,027[11] - The largest shareholder, Xinjiang Hualing Industrial Trade Group, holds 19.86% of shares[11] Expenses - The company reported a 74.74% increase in selling expenses to CNY 1.33 million compared to CNY 0.76 million in the previous year[16] - Financial expenses surged by 1161.25% to CNY 0.57 million from CNY 0.04 million year-over-year[16] - The company experienced a 75.92% reduction in income tax expenses to CNY 0.83 million from CNY 3.44 million[17] - Management expenses for Q1 2020 were ¥15,373,837.32, an increase of 14.2% compared to ¥13,456,342.84 in Q1 2019[31] Other Financial Metrics - Non-recurring gains and losses totaled CNY 1,608,515.94[8] - Investment income decreased by 90.09% to CNY 0.05 million from CNY 0.53 million in the previous year[16] - Long-term equity investments remained relatively stable, with a slight increase from CNY 51,503,259.60 to CNY 51,529,307.19[22] - The company has a long-term equity investment valued at 51,503,259.60 RMB[44]

2019 年年度报告 公司代码：600721 公司简称：*ST 百花 新疆百花村股份有限公司 2019 年年度报告 1 / 185 2019 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 未出席董事情况 未出席董事职务 未出席董事姓名 未出席董事的原因说明 被委托人姓名 董事 张孝清 因个人原因 无委托 三、 西安希格玛会计师事务所为本公司出具了标准无保留意见的审计报告。 四、 公司负责人郑彩红、主管会计工作负责人蔡子云及会计机构负责人（会计主管人员）余涛声 明：保证年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 经希格玛会计师事务所审计认定，公司2019年度母公司净利润-3,672,950.36元，母公司实际累 计可供分配利润为-1,678,504,740.43元。鉴于公司累计可供股东分配的利润为负数，公司2019年度 不进行现金股利分配，也不进行资本公积转增股本。 六、 前瞻性陈述的风险声明 □适用 √不适用 七、 ...

2019 年第三季度报告 公司代码：600721 公司简称：*ST 百花 新疆百花村股份有限公司 2019 年第三季度报告 1 / 23 | 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 7 | | 四、 | 附录 | 9 | 2019 年第三季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人郑彩红、主管会计工作负责人蔡子云及会计机构负责人（会计主管人员）余涛保 证季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 3 / 23 单位：元 币种：人民币 本报告期末 上年度末 本报告期末比上年度末增 减(%) 总资产 1,211,038,006.95 1,248,330,745.21 -2.99 归属于上市公司 股东的净资产 ...

Financial Performance - The company's operating revenue for the first half of 2019 was ¥133,148,773.65, a decrease of 39.49% compared to ¥220,035,072.93 in the same period last year[16]. - The net profit attributable to shareholders for the first half of 2019 was ¥37,486,550.58, down 29.88% from ¥53,462,191.01 in the previous year[16]. - The net cash flow from operating activities was negative at -¥42,877,591.50, a decline of 186.72% compared to ¥49,445,060.46 in the same period last year[16]. - Basic earnings per share for the first half of 2019 were ¥0.0936, down 29.89% from ¥0.1335 in the same period last year[17]. - The total operating revenue for the first half of 2019 was CNY 133 million, a decrease of 39.49% compared to the same period last year[32]. - The net profit attributable to shareholders of the listed company was CNY 37 million, down 29.88% year-on-year[32]. - The revenue from Huawai Pharmaceutical Group was CNY 118.6 million, a decrease of 13.33% year-on-year, with a net profit of CNY 31.1 million, down 42.59%[33]. - The company’s R&D revenue was CNY 75.16 million, a decrease of CNY 26.91 million from CNY 102.07 million in the previous year[34]. - The company’s labor costs increased by 56.16% year-on-year, amounting to CNY 53.99 million, which constituted 45.52% of the current operating revenue[35]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,242,682,519.16, a slight decrease of 0.45% from ¥1,248,330,745.21 at the end of the previous year[16]. - The net assets attributable to shareholders increased by 4.96% to ¥958,942,299.21 from ¥913,643,129.67 at the end of the previous year[16]. - As of June 30, 2019, the total assets of the company amounted to CNY 1.243 billion, with equity attributable to the parent company at CNY 959 million[32]. - The company's total liabilities decreased to ¥273,202,860.53 from ¥328,746,240.15, reflecting a reduction of about 16.9%[104]. - The company's current assets totaled ¥606,368,395.55, down from ¥620,653,640.54 at the end of 2018, indicating a decrease of approximately 2.3%[102]. Cash Flow - The company’s cash and cash equivalents decreased by 72.86% to ¥27,242,065.02, mainly due to payments for investments and operational expenses[44]. - The company reported cash and cash equivalents of ¥27,242,065.02, down from ¥100,379,375.83, indicating a significant decrease of approximately 72.9%[102]. - Cash flow from operating activities for the first half of 2019 was ¥105,809,992.11, down from ¥188,999,094.87 in the first half of 2018, a decrease of approximately 43.9%[117]. - Operating cash inflow totaled CNY 131,860,953.08, a decrease from CNY 223,291,452.91 in the previous period, reflecting a decline of approximately 41%[118]. - The ending cash and cash equivalents balance was CNY 27,242,065.02, down from CNY 64,495,756.40 in the previous period, indicating a decrease of approximately 58%[119]. Business Strategy and Operations - The company is focusing on the development of innovative drugs in oncology, hypertension, and diabetes, utilizing both client-commissioned and independent research approaches[23]. - The CRO service model is designed to save time and costs for pharmaceutical companies, reflecting a growing trend in the industry towards outsourcing[24]. - The company has established a collaborative effect through its subsidiaries, enhancing service range and operational efficiency[30]. - The company is optimizing its business structure by divesting from non-core operations and focusing on the pharmaceutical health sector[38]. - The company has committed to not engaging in any form of drug research and development business that could compete with its listed operations[60]. Shareholder and Equity Information - The company has not proposed any profit distribution plan for the reporting period[5]. - The company has not proposed any profit distribution or capital reserve transfer plans for the half-year period[56]. - The total number of ordinary shareholders as of the end of the reporting period is 15,342[88]. - The company has not made any changes to its share capital structure during the reporting period[86]. - The largest shareholder, Xinjiang Production and Construction Corps Sixth Division State-owned Assets Management Co., held 79,525,087 shares, accounting for 100% of the total shares[89]. Compliance and Legal Matters - The company has not faced any significant litigation or administrative penalties in the past five years[67]. - The company is currently involved in arbitration regarding a dispute over the "Profit Forecast Supplement Agreement" from 2018[71]. - The company guarantees that Huawai Pharmaceutical will maintain normal and legal operational status until the completion of equity transfer[65]. - The company will continue to strictly adhere to legal and regulatory requirements in conducting related transactions to protect the rights of Baihuacun and its shareholders[61]. Future Outlook - The cumulative net profit forecast for the year may face significant fluctuations compared to the same period last year[54]. - The company plans to enhance its market expansion strategies in the upcoming quarters[129]. - The company has committed to compensating for any losses incurred by Huawai Pharmaceutical due to violations of agreements[62]. Accounting and Financial Reporting - The company appointed Sigma Accounting Firm as the auditor for the 2019 fiscal year[70]. - The company’s financial statements comply with the relevant accounting standards and accurately reflect its financial position as of June 30, 2019[157]. - The company’s accounting policies are based on actual operating characteristics and comply with the relevant accounting standards[156]. - The company’s financial reporting period follows the calendar year, from January 1 to December 31[158].

证券代码：600721 证券简称：*ST 百花 公告编号：2019-048 新疆百花村股份有限公司关于参加 2019 年新疆辖区 上市公司投资者集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及 连带责任。 为便于广大投资者更深入全面地了解公司情况、发展战略、经营 状况、融资计划、可持续发展等投资者所关心的问题，公司定于 2019 年 7 月 26 日下午 15:00-17:30 参加由新疆上市公司协会联合深圳市全 景网络有限公司组织开展的 2019 年新疆辖区上市公司投资者集体接 待日活动。现将有关事项公告如下： 本次集体接待日活动将在深圳市全景网络有限公司提供的网上 平台，采取网络远程的方式举行，投资者可以登录"全景·路演天下" 网站（http://rs.p5w.net/）或关注微信公众号：全景财经（微信号： p5w2012），参与公司本次投资者集体接待日活动，活动时间为 2019 年 7 月 26 日（星期五）15:00 至 17:30。 出席本次集体接待日的人员有：公司董事长郑彩红、常务副总经 理吕政田、 ...

Financial Performance - The company's net profit for 2018 was -799,158,062.38 CNY, with a cumulative distributable profit of -1,807,404,994.82 CNY, resulting in no cash dividend distribution for the year [6]. - Total revenue for 2018 was 419,189,442.94 CNY, a slight decrease of 0.07% compared to 419,502,543.16 CNY in 2017 [22]. - The net loss attributable to shareholders for 2018 was -807,864,681.82 CNY, representing a 43.21% increase in losses compared to -564,115,292.91 CNY in 2017 [22]. - The basic earnings per share for 2018 was -2.0177 CNY, a decline of 43.21% from -1.4089 CNY in 2017 [24]. - The weighted average return on equity for 2018 was -61.31%, a decrease of 33.15 percentage points from -28.16% in 2017 [24]. - The company reported a significant increase in cash flow from operating activities, generating 80,553,717.37 CNY in 2018, compared to a negative cash flow of -50,260,023.26 CNY in 2017, marking a 260.27% improvement [22]. - The company's total assets decreased by 38.59% to 1,248,330,745.21 CNY at the end of 2018, down from 2,032,765,005.73 CNY in 2017 [23]. - The company's net assets attributable to shareholders decreased by 46.93% to 913,643,129.67 CNY at the end of 2018, down from 1,721,507,811.49 CNY in 2017 [23]. Operational Highlights - The company has faced continuous net losses for the last two accounting years, which may lead to a delisting risk warning as per the Shanghai Stock Exchange regulations [7]. - The company did not engage in any non-operating fund occupation by controlling shareholders or related parties during the reporting period [7]. - In Q1 2018, the company reported revenue of ¥111,926,381.39, which decreased to ¥58,672,336.96 in Q4 2018, indicating a significant decline in revenue over the year [26]. - The net profit attributable to shareholders was ¥31,614,198.05 in Q1 2018, but the company faced a loss of ¥877,945,622.59 in Q4 2018, reflecting a downward trend in profitability [26]. - The net cash flow from operating activities showed fluctuations, with a positive cash flow of ¥3,903,750.27 in Q1 and a substantial increase to ¥61,269,325.32 in Q4 2018 [26]. Research and Development - The company’s main business focuses on drug discovery, research, and technology services, providing integrated solutions for new drug development [34]. - The company has a strong focus on innovative drug development in areas such as oncology, hypertension, and diabetes, targeting both novel and clinically validated drug targets [34]. - The company has established multiple mature technology platforms, including chiral synthesis and controlled-release formulation technologies, enhancing its competitive edge in drug development [40]. - The company plans to strengthen its core pharmaceutical research and development business while expanding its capabilities in clinical services and technology transfer [48]. - The company aims to enhance its research and development capabilities by increasing investment in biopharmaceuticals and expanding its CRO services to improve market competitiveness [80]. Financial Management and Strategy - The company has committed to enhancing its internal control systems and risk management practices to mitigate financial risks [46]. - The company has initiated a comprehensive asset management review to improve operational efficiency and asset utilization [47]. - The company plans to achieve a total revenue of 3.18 billion in 2019, with 2.95 billion expected from the pharmaceutical sector [81]. - The company intends to establish an industrial merger fund to enhance capital strength and promote growth through mergers and acquisitions [80]. - The company is focusing on expanding its market presence and enhancing its operational scale through strategic acquisitions in the pharmaceutical industry [80]. Shareholder and Governance - The company has not proposed any cash dividend distribution plans despite having positive distributable profits for the reporting period [90]. - The board of directors is required to develop a profit distribution plan based on the company's operational conditions and market environment when profits meet distribution criteria [87]. - The company has not distributed dividends in the past three years, with net profits reported as negative in 2018 (-807.86 million RMB) and 2017 (-564.12 million RMB) [89]. - The company has performance commitments for net profits of at least 1.47 billion RMB for 2018 and a cumulative net profit of no less than 370 million RMB from 2016 to 2018 [91]. - The company has maintained a clear ownership structure with no disputes or potential disputes regarding its equity holdings [107]. Compliance and Risk Management - The company has ensured compliance with relevant laws and regulations, with no violations reported [110]. - The company has not faced any significant lawsuits or administrative penalties that could materially impact its operations [113]. - The company has a complete business system and operates independently in the market without significant competition from related parties [112]. - The company has actively engaged with investors through various communication channels to address their concerns [184]. - The company maintained effective internal control over financial reporting as of December 31, 2018, with no significant deficiencies identified [192]. Employee and Management - The company has a total of 723 employees, with 55 in the parent company and 668 in major subsidiaries [176]. - The company has implemented a composite salary system consisting of base salary, performance pay, and various subsidies [177]. - The total remuneration for all directors, supervisors, and senior management during the reporting period amounted to 219.03 million [172]. - The management team has extensive experience in the healthcare and pharmaceutical industries, enhancing the company's strategic positioning [169]. - The company has established a clear decision-making process for executive compensation, ensuring transparency and accountability [172].

Financial Performance - Net profit attributable to shareholders was CNY 26,477,959.08, down 16.25% year-on-year[6]. - Operating revenue for the period was CNY 70,454,860.94, representing a decline of 37.05% compared to the same period last year[6]. - The net profit after deducting non-recurring gains and losses was CNY 25,162,949.03, down 18.97% year-on-year[6]. - The company's net profit from investment increased significantly to CNY 5.29 million, up 1706.56% from CNY 0.29 million year-on-year, primarily due to gains from the disposal of long-term equity investments[16]. - Total operating revenue for Q1 2019 was ¥70,454,860.94, a decrease of 37% compared to ¥111,926,381.39 in Q1 2018[28]. - Net profit for Q1 2019 was ¥26,308,541.27, a decline of 16% from ¥31,574,329.11 in Q1 2018[29]. - Total profit for Q1 2019 was ¥29,753,434.13, down 20% from ¥36,993,756.17 in Q1 2018[29]. - The basic and diluted earnings per share for Q1 2019 were ¥0.0661, compared to ¥0.0790 in Q1 2018[30]. Cash Flow - The net cash flow from operating activities was negative CNY 48,569,318.25, a significant decrease of 1,344.17% year-on-year[6]. - The net cash flow from operating activities was -52,196,452.81 RMB, a significant decline compared to 26,463,307.07 RMB in the same period last year, indicating a negative cash flow trend[36]. - The total cash outflow from operating activities reached 76,406,053.17 RMB, compared to 25,562,928.88 RMB in the previous year, indicating a substantial increase in cash outflows[36]. - The company reported a total cash inflow from operating activities of 24,209,600.36 RMB, down from 52,026,235.95 RMB year-over-year, indicating a decline in operational performance[36]. - The company received 19,178,293.78 RMB from other operating activities, a significant increase from 3,668,084.66 RMB in the previous year, showing improved cash inflow from this segment[36]. - The company paid 57,061,608.24 RMB in other operating cash payments, a notable rise from 13,458,278.12 RMB in the same quarter last year, indicating increased operational costs[36]. - Cash and cash equivalents dropped significantly from CNY 17,512,665.93 to CNY 2,536,493.18, a decrease of approximately 85.5%[25]. - Cash and cash equivalents at the end of the period were 2,536,493.18 RMB, down from 51,831,190.52 RMB at the end of the same quarter last year, reflecting a decrease of approximately 95%[37]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,235,967,627.94, a decrease of 0.99% compared to the end of the previous year[6]. - Current liabilities decreased from CNY 288,616,418.24 to CNY 247,967,849.68, a reduction of about 14.1%[23]. - Non-current liabilities decreased from CNY 40,129,821.91 to CNY 37,290,338.66, a decrease of approximately 7.2%[23]. - Total liabilities decreased from CNY 328,746,240.15 to CNY 285,258,188.34, a decline of around 13.2%[23]. - The company's total current assets as of March 31, 2019, were CNY 602.82 million, a slight decrease from CNY 620.65 million at the end of 2018[21]. - The balance of prepaid accounts at the end of the reporting period was CNY 32.77 million, an increase of 183.78% from CNY 11.55 million at the beginning of the period, mainly due to prepaid purchase amounts[15]. - The balance of other receivables increased to CNY 6.14 million, a rise of 229.07% from CNY 1.87 million at the beginning of the period, mainly due to receivables from the transfer of 51% equity in Tianjin Trading Company[15]. - The balance of accounts payable decreased to CNY 46.60 million, down 36.18% from CNY 73.02 million at the beginning of the period, mainly due to the reduction in the scope of consolidation after the equity transfer[15]. - Total equity increased from CNY 919,584,505.06 to CNY 950,709,439.60, an increase of approximately 3.4%[23]. Shareholder Information - The total number of shareholders at the end of the reporting period was 18,998[12]. - The largest shareholder, Xinjiang Production and Construction Corps, held 19.86% of the shares[12]. Other Income and Gains - The company reported non-recurring gains of CNY 1,315,010.05 for the period[11]. - The company reported other income of CNY 1.56 million, an increase of 2038.27% from CNY 0.07 million year-on-year, mainly due to government subsidies from Nanjing Huawei Company[16]. - Investment income for Q1 2019 was ¥5,289,590.05, compared to ¥292,846.62 in Q1 2018, indicating a substantial increase[28].

Financial Performance - The company's net profit for 2018 was -799,158,062.38 CNY, with a cumulative distributable profit of -1,807,404,994.82 CNY, resulting in no cash dividend distribution for the year [6]. - Operating revenue for 2018 was 419,189,442.94 CNY, a slight decrease of 0.07% compared to 419,502,543.16 CNY in 2017 [22]. - The net loss attributable to shareholders for 2018 was -807,864,681.82 CNY, representing a 43.21% increase in losses compared to -564,115,292.91 CNY in 2017 [22]. - The company's total assets decreased by 38.59% to 1,248,330,745.21 CNY at the end of 2018, down from 2,032,765,005.73 CNY in 2017 [23]. - The basic earnings per share for 2018 was -2.0177 CNY, a decline of 43.21% from -1.4089 CNY in 2017 [24]. - The weighted average return on equity for 2018 was -61.31%, a decrease of 33.15 percentage points from -28.16% in 2017 [24]. - Cash flow from operating activities improved significantly to 80,553,717.37 CNY in 2018, compared to -50,260,023.26 CNY in 2017, marking a 260.27% increase [22]. - The company's net assets attributable to shareholders decreased by 46.93% to 913,643,129.67 CNY at the end of 2018, down from 1,721,507,811.49 CNY in 2017 [23]. - The company has faced continuous net losses for the last two accounting years, which may lead to a delisting risk warning as per the Shanghai Stock Exchange regulations [7]. Revenue and Profitability Trends - In Q1 2018, the company reported revenue of ¥111,926,381.39, which decreased to ¥58,672,336.96 in Q4 2018, indicating a significant decline in revenue over the year [26]. - The net profit attributable to shareholders was ¥31,614,198.05 in Q1 2018, but the company faced a loss of ¥877,945,622.59 in Q4 2018, reflecting a downward trend in profitability [26]. - The net cash flow from operating activities showed fluctuations, with a positive cash flow of ¥3,903,750.27 in Q1 and a substantial increase to ¥61,269,325.32 in Q4 2018 [26]. - The company reported non-recurring gains of ¥10,936,376.25 for the year, which included government subsidies and asset disposal gains [28]. - The total operating revenue for 2018 was 419 million yuan, a decrease of 31.31 million yuan compared to the previous year, resulting in a net loss attributable to shareholders of 808 million yuan [43]. Asset Management and Investments - The company recognized an impairment loss of 908.18 million yuan for the goodwill related to the acquisition of Nanjing Huawai, with a remaining goodwill of 173 million yuan [44]. - The company has developed multiple mature technology platforms in drug research, including chiral synthesis and controlled-release formulation technologies [40]. - The company has a low turnover rate among high-end technical personnel, ensuring a stable and strong core research team [41]. - The company plans to enhance its core competitiveness in the pharmaceutical sector by expanding research and development, technology transfer, and clinical services [48]. - The company aims to improve the profitability of traditional businesses by adjusting and transforming existing operations [48]. Market and Competitive Landscape - The company is actively engaged in innovative drug development, particularly in oncology, hypertension, and diabetes, targeting both novel and clinically validated drug targets [34]. - The company is facing challenges in its foreign trade business due to rising domestic operating costs and fluctuations in Sino-U.S. trade relations [43]. - The company plans to expand its pharmaceutical research and development capabilities, focusing on technology transfer and development income [57]. - The company faces risks related to a potential decline in R&D business due to new regulations affecting the development and transfer of "old category 3" drugs [84]. - Rising R&D costs are anticipated as the company expands its pharmaceutical services, leading to increased total costs in the medical and healthcare sectors [84]. Corporate Governance and Compliance - The company has implemented a comprehensive internal control system to strengthen supervision and mitigate financial risks [46]. - The company has maintained a strict separation from its controlling shareholder in terms of business, personnel, assets, and finances [182]. - The company has ensured timely and accurate information disclosure, adhering to regulatory requirements [184]. - The board of directors has actively participated in meetings, with attendance rates for key members being high [186]. - The company has not faced any penalties from securities regulatory authorities in the past three years [175]. Shareholder Structure and Management - The total number of ordinary shares is 400,386,394, which accounts for 100% of the shares [144]. - The top shareholder, Xinjiang Production and Construction Corps, holds 79,525,087 shares, representing 19.86% of the total shares [151]. - The company has a total of 42,962,409 shares under limited sale conditions, which will be tradable after 12 months from the issuance completion date [154]. - The company has a management salary scheme that determines the remuneration for directors and supervisors [172]. - The current board includes experienced professionals from various sectors, enhancing the company's governance [170]. Future Outlook and Strategic Initiatives - The company plans to achieve a total revenue of 3.18 billion in 2019, with 2.95 billion expected from the pharmaceutical sector [81]. - The company aims to enhance its research and development capabilities by increasing investment in biopharmaceuticals and expanding its CRO services to improve market competitiveness [80]. - The company plans to enter new markets in Europe, with an initial investment of $150 million [102]. - The company is investing $200 million in research and development for new technologies aimed at improving user experience [106]. - The company is focusing on expanding its market presence and enhancing its product offerings through strategic acquisitions in the pharmaceutical industry [80].

Financial Performance - Revenue for the first nine months reached CNY 360,517,105.98, an increase of 11.45% year-on-year[7] - Net profit attributable to shareholders was CNY 70,080,940.77, a slight increase of 0.51% compared to the previous year[7] - Basic earnings per share for the first nine months was CNY 0.1750, up by 0.52% from CNY 0.1741[7] - The weighted average return on equity increased by 0.99 percentage points to 3.99%[7] - Total operating revenue for Q3 2018 was CNY 140,482,033.05, a significant increase from CNY 65,351,741.99 in Q3 2017, representing a growth of 115.4%[28] - Net profit for Q3 2018 was CNY 16,696,837.26, down from CNY 25,565,799.34 in Q3 2017, reflecting a decrease of 34.7%[28] - The net profit attributable to the parent company for Q3 2018 was ¥16,618,749.76, compared to ¥25,622,662.14 in the previous quarter, indicating a decrease of about 35%[29] - The total comprehensive income for Q3 2018 was ¥2,033,825.77, compared to a loss of ¥640,188.53 in the same period last year, marking a turnaround[32] Cash Flow - Operating cash flow decreased by 53.17% to CNY 19,284,392.05 for the first nine months compared to the same period last year[6] - The net cash flow from operating activities is 19.28 million yuan, a decrease of 53.10% from the previous year's 41.18 million yuan, mainly due to a decrease in cash received from sales of goods and services[16] - The net cash flow from investing activities is -95.79 million yuan, a decrease of 36.24% from the previous year's -70.32 million yuan, primarily due to increased cash payments for fixed asset purchases and investments[16] - The company's cash flow from operating activities was positively impacted by a substantial increase in cash received from sales, which reached ¥98,810,153.51 compared to ¥21,674,928.69 last year[36] - Net cash flow from operating activities improved to ¥44,818,304.08, compared to a negative cash flow of ¥5,320,092.08 in the same period last year[36] - The company incurred financial expenses of ¥235,073.45 in Q3 2018, a decrease from ¥398,930.89 in the previous quarter, indicating improved cost management[32] Assets and Liabilities - Total assets increased by 4.62% to CNY 2,126,604,584.38 compared to the end of the previous year[6] - Net assets attributable to shareholders rose by 4.07% to CNY 1,791,588,752.26 year-on-year[6] - The ending balance of cash and cash equivalents is 45.61 million yuan, a decrease of 63.57% from the beginning balance of 125.19 million yuan, primarily due to the purchase of bank wealth management products and payments for equipment and construction projects[12] - The ending balance of accounts receivable is 191.61 million yuan, an increase of 82.35% from the beginning balance of 105.08 million yuan, mainly due to increased receivables from pharmaceutical research and clinical trial services[12] - The ending balance of other current assets is 52.35 million yuan, an increase of 934.11% from the beginning balance of 5.06 million yuan, primarily due to the purchase of bank wealth management products[13] - The ending balance of fixed assets is 202.44 million yuan, an increase of 81.08% from the beginning balance of 111.80 million yuan, mainly due to the transfer of construction projects to fixed assets[14] - The ending balance of accounts payable is 48.30 million yuan, an increase of 54.69% from the beginning balance of 31.22 million yuan, primarily due to the transfer of commercial acceptance bills and increased estimated costs for clinical projects[15] - Total liabilities decreased to CNY 91,525,012.90 from CNY 112,910,657.74 at the start of the year, showing a reduction of 18.9%[25] - The company's cash and cash equivalents decreased to CNY 8,903,964.13 from CNY 28,146,935.08 at the beginning of the year, a decline of 68.4%[24] Shareholder Information - The total number of shareholders reached 24,869 as of the report date[9] - The largest shareholder, Xinjiang Production and Construction Corps, holds 19.86% of the shares[10] Other Information - The company reported a government subsidy of CNY 710,753.18 for the current period[8] - The company plans to hire a professional institution to conduct goodwill impairment testing, with the work currently ongoing and uncertain outcomes[18]